Showing 3161-3170 of 5646 results for "".
- At-Home App Helps Patients Stay Engaged and Adherent to Vision Monitoring Remotelyhttps://modernod.com/news/at-home-app-helps-patients-stay-engaged-and-adherent-to-vision-monitoring-remotely/2479208/Novartis announced it has begun a US pilot program for OdySight, a clinically tested mobile application designed to help monitor vision remotely. Recent changes to public health protocols, paired with a growing patient population and existing treatment burden, have placed an emphasis on vi
- Oculis Announces Positive Data From Two Proof-of-Concept Phase 2 Trials With OCS-02 in Dry Eye Disease and Acute Anterior Uveitishttps://modernod.com/news/oculis-announces-positive-data-from-two-proof-of-concept-phase-2-trials-with-ocs-02-in-dry-eye-disease-and-acute-anterior-uveitis/2479192/Oculis announced positive data from two clinical proof of concept phase 2 trials with OCS-02, its novel, topical anti-TNF alpha antibody fragment candidate, in dry eye disease (DED) and acute anterior uveitis (AAU). The data were presented for the first time at ARVO 2021, the annual meeting of th
- Bio-Tissue to Present Webinar in 3-D Showcasing New Treatment Regimen to Diagnose and Treat Mechanical Dry Eyehttps://modernod.com/news/bio-tissue-to-present-webinar-in-3-d-showcasing-new-treatment-regimen-to-diagnose-and-treat-mechanical-dry-eye/2479188/Bio-Tissue announced today that it will present a special 3-D webinar on Wednesday, May 19, 2021, from 8:30 pm to 9:30 pm EDT, hosted by Neel Desai, MD, who will demonstrate his novel surgical technique known as Reservoir Restoration to treat Mechanical Dry Eye (MDE). He will also discuss how to
- Mount Sinai Ophthalmologists Develop New Technique to Assess Progression of Sickle Cell Retinopathyhttps://modernod.com/news/mount-sinai-ophthalmologists-develop-new-technique-to-assess-progression-of-sickle-cell-retinopathy/2479189/Ophthalmologists at New York Eye and Ear Infirmary of Mount Sinai have created a new technique to evaluate patients with sickle cell retinopathy and assess the disease before it progresses and leads to permanent vision loss. Using optical coherence tomography (OCT) angiography, the resear
- ProQR Therapeutics and Yarrow Biotechnology Announce Exclusive License and Discovery Collaboration for Undisclosed Ophthalmic Targethttps://modernod.com/news/proqr-therapeutics-and-yarrow-biotechnology-announce-exclusive-license-and-discovery-collaboration-for-undisclosed-ophthalmic-target/2479165/RTW Investments and ProQR Therapeutics announced that Yarrow Biotechnology, a company newly created by RTW, has in-licensed exclusive rights to ProQR’s antisense oligonucleotide technology (ASO) to develop and commercialize potential therapies for an undisclosed non-ophthalmic target. Yarrow is f
- Lineage Cell: OpRegen Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With GAhttps://modernod.com/news/lineage-cell-opregen-clinical-data-continues-to-demonstrate-improvements-in-patients-with-dry-amd-with-ga/2479160/Lineage Cell Therapeutics announced that updated interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2021). OpRegen is an investigational
- Pfizer, BioNTech Seek EU Nod to Allow COVID-19 Vaccine Use in Younger Teenshttps://modernod.com/news/pfizer-biontech-seek-eu-nod-to-allow-covid-19-vaccine-use-in-younger-teens/2479158/Pfizer and BioNTech said they have asked the European Medicines Agency (EMA) to extend the conditional marketing authorization for their COVID-19 vaccine Comirnaty to adolescents 12 to 15 years of age. The companies recently made a similar request to the FDA for the vaccine, which is already auth
- Oxurion NV Presenting Scientific Data at ARVO 2021 Annual Meetinghttps://modernod.com/news/oxurion-nv-presenting-scientific-data-at-arvo-2021-annual-meeting/2479144/Oxurion NV is announcing the presentation of novel scientific data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting which is held on May 1-7, 2021. The details of the presentation are as follows: Title: The Mouse Sodium Iodate Mo
- Alcon to Acquire US Commercialization Rights to Glaucoma Eye Drop Simbrinzahttps://modernod.com/news/alcon-to-acquire-us-commercialization-rights-to-ophthalmic-eye-drop-simbrinza/2479138/Alcon announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis. Under terms of the deal, Alcon will pay $355 million at closing, which is expected to occur in the sec
- Glaukos Announces Global Licensing Agreement Amendment with Intratus to Include the Treatment of Presbyopiahttps://modernod.com/news/glaukos-announces-global-licensing-agreement-amendment-with-intratus-to-include-the-treatment-of-presbyopia/2479115/Glaukos announced that it has entered into an amended licensing agreement with Intratus under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, noninvasive drug delivery platform (the Eyelid Drug Delivery Platform